Wednesday, June 15, 2011

Ken Clarke Appointed General Manager of OralDNA® Labs Inc.

Brentwood, TN – June 9th, 2011 – OralDNA® Labs Inc. (, leaders in advancing wellness in dentistry through salivary diagnostics, and a subsidiary of Quest Diagnostics® (NYSE: DGX), recently appointed Ken Clarke as General Manager.   He will report to Dermot Shorten, Vice President, Office of the Chairman, and will be based in Brentwood, Tennessee.


“As one of the founders of OralDNA, Ken has invaluable firsthand marketplace experience,” Shorten said.  “He understands the high potential of this business and is focused on its continued growth. He will help us accelerate our momentum.”


Prior to the creation of OralDNA in 2008, Ken provided strategic planning and project implementation services for major hospitals and medical laboratories through Clarke Consulting, which he led from 2006 through 2007 in Nashville, TN. Before that, Ken served as Vice President of Operations for LabOne in Cincinnati, OH, where he managed a centralized laboratory and six hospital laboratories.


Ken has also worked as Administrative Director of the Pathology Laboratories at Northwestern Memorial Hospital, a major academic hospital in the Chicago area.  Ken received a bachelor’s degree from Vanderbilt University and master’s degrees in healthcare administration and business administration from Washington University in St. Louis, MO.


This announcement comes just months after OralDNA Labs appointed dental industry veteran Michael Dunn to the newly created position of Vice President of Marketing.  Dunn was most recently the Sales & Marketing Director for CDB Corporation, the leading OEM supplier of ceramic and composite orthodontic brackets.  Prior to CDB Corporation, he held various marketing posts over several years at Sirona Dental Systems, including Director of Marketing, CAD/CAM Systems.  He is a graduate of the University of North Carolina at Charlotte, where he earned a BA in mathematics.


About OralDNA® Labs Inc. (

OralDNA® Labs Inc., a subsidiary of Quest Diagnostics® (NYSE: DGX), is a leader in advancing wellness in dentistry through salivary diagnostics. The company’s goal is to help the dental profession achieve better clinical outcomes by providing reliable, definitive, and cost-

effective clinical tests that drive the detection and prognosis of disease at an earlier, more

treatable stage.  Innovative salivary diagnostic tests from OralDNA® Labs are fundamental

elements of a patient’s wellness plan. OralDNA® currently offers three DNA-Polymerase Chain Reaction (PCR) tests for periodontal disease and oral HPV:

  • MyPerioPath® identifies the type and concentration of specific perio-pathogenic bacteria that are known to cause periodontal disease and helps support clinicians with better risk assessment and personalized treatment options for more predictable patient outcomes.

  • MyPerioID® PST® identifies individual genetic susceptibility to periodontal disease and enables clinicians to establish which patients are at increased risk for more severe periodontal infections due to an exaggerated immune response.


  • OraRisk® HPV is a non-invasive, easy-to-use screening tool to identify the type(s) of oral HPV, a mucosal viral infection that could potentially lead to oral cancer, and in turn, enables the clinician to establish increased risk for oral cancer and determine appropriate referral and monitoring conditions.

About Quest Diagnostics®

Quest Diagnostics® is the world's leading provider of diagnostic testing, information, and services that patients and clinicians need to make better healthcare decisions.  The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.  Quest Diagnostics® is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at

No comments:

Post a Comment